With patents for many NBCDs soon to expire, the need for regulatory guidance regarding follow-on versions of these products is crucial.
Scott Kolodny, MD
Advertisement
Articles by Scott Kolodny, MD
Advertisement
Latest Updated Articles
Safety Considerations for Follow-On Non-Biologic Complex DrugsPublished: June 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
3
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
4
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
